AzTrials
AzTrials

AnxietyPhase 2NCT02427568

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

A Phase 2 study testing Midomafetamine HCl and Therapy in people with Anxiety, run by Resilient Pharmaceuticals at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy? Researchers will compare people… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Anxiety
What is being tested?
Midomafetamine HCl and Therapy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
18 participants
Where
1 siteUnited States
Study dates
14 May 2015to 17 May 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosed with life-threatening cancer or non-dementing neurological illness, which can be ongoing or in remission, but with a possibility of recurrence
  • Prognosis of at least nine months life expectancy from the time of screening
  • Have anxiety as a result of facing their illness
  • Are at least 18 years old
  • Are willing to refrain from taking any psychiatric medications during the study period;
  • Are willing to commit to medication dosing, experimental sessions, follow-up sessions, and to complete evaluation instruments
Show all 12Show fewer
  • Are willing to remain overnight at the study site after each experimental session until after the integrative session occurring the next morning
  • Must sign a medical release for the investigators to communicate directly with their therapist and doctors;
  • Are willing to select up to three observers who will complete observer measures of subject attitudes and behavior
  • Negative pregnancy test if able to bear children and agree to use effective birth control
  • Are proficient in speaking and reading English
  • Agree to have all psychotherapy sessions recorded to audio/video.

Who cannot join

  • Are pregnant or nursing, or if a woman who can have children, those who are not practicing an effective means of birth control;
  • Weigh less than 48 kg
  • Are abusing illegal drugs
  • Are unable to give adequate informed consent
  • Upon review of past, current drugs/medication must not be on or have taken a medication that is exclusionary
  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study
  • Have used "Ecstasy" (material represented as containing MDMA) at least once within twelve months of enrollment.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Offices of Philip Wolfson MD

    San Anselmo, California, 94960

Other trials in United States

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with anxiety associated with a life-threatening illness. The main question it aims to answer is: Does anxiety decrease in people receiving two sessions of MDMA-assisted therapy?

Researchers will compare people receiving placebo with therapy to people receiving MDMA-assisted therapy.

  • Participants will undergo three non-drug preparatory therapy sessions before their first blinded session of MDMA or placebo with therapy.
  • Each medication session will be followed by three non-drug integrative therapy sessions.
  • After the second blinded medication session, participants receiving MDMA will complete a third open-label medication session.
  • Participants who received placebo will be given the option to crossover and receive three sessions of assisted therapy.
Read the detailed description

This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study in 18 participants comparing the effects of MDMA-assisted therapy vs. placebo with therapy. Thirteen participants were randomized to the active dose condition of 125 mg of MDMA HCl (plus an optional supplemental dose of 62.5 mg MDMA HCl) with therapy and five participants were randomized to the placebo with therapy condition. The study consisted of two blinded experimental sessions of MDMA-assisted therapy or placebo with therapy, each session lasting six to eight hours and scheduled two to four weeks apart. Each participant was unblinded one month after their second experimental session in Stage 1. After unblinding, participants receiving MDMA were to complete a third open-label experimental session of MDMA-assisted therapy and participants who originally received placebo had the opportunity to cross over to open-label Stage 2 and receive active MDMA-assisted therapy in 3 sessions.

The primary objective of the study is to assess changes in trait anxiety in subjects receiving active dose MDMA compared to those receiving placebo as measured by State-Trait Anxiety Index (STAI) Trait scores from Baseline to the Primary Endpoint (one month after the second experimental session).

Conditions
Anxiety
Being tested
Midomafetamine HCl, Placebo, Therapy
Keywords
Anxiety, MDMA, Life-threatening illness, Therapy, midomafetamine
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Midomafetamine HClDrug

    Also called 3,4-methylenedioxymethamphetamine, Midomafetamine, MDMA

    Two sessions of MDMA-assisted therapy lasting six to eight hours, scheduled two to four weeks apart.

  • PlaceboDrug

    Also called Inactive placebo

    Two sessions of placebo with therapy lasting six to eight hours, scheduled two to four weeks apart.

  • TherapyBehavioural

    Manualized therapy

Study groups in NCT02427568
Study groupRoleWhat they receive
Placebo with therapyPlacebo comparatorInactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
Receives: Drug: Placebo; Behavioral: Therapy
MDMA-assisted therapy (125 mg)Experimental125 mg midomafetamine HCl administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg.
Receives: Drug: Midomafetamine HCl; Behavioral: Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint

    The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.

    The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure was intended to target those anxiety symptoms that are chronic and pervasive.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  2. Primary Endpoint STAI Trait Score

    The State-Trait Anxiety Inventory (STAI) is a 20-item self-report measure of intensity of anxiety. Each item consists of a 4-point Likert rating scale ranging from 1 ('Not at all') to 4 ('Very Much So'), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.

    The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

    Measured: One month post-2nd experimental session

Secondary outcomes (9)
  1. Change in STAI State Score From Baseline to Primary Endpoint

    The state subscale of the STAI (STAI-S) is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Like the trait subscale, participants respond to each item on the state subscale by selecting a response from a 4-point Likert scale ranging from 4 ("Not at all") to 1 ("Very much so"), with higher scores indicating greater anxiety. Items were summed for a total score that ranged from 20 to 80.

    The STAI differentiates between State Anxiety, defined as "anxiety experienced in reaction to a specific environmental circumstance," and Trait Anxiety, defined as "long-standing nervous affect or anxiety disorder." The use of the trait subscale as the primary outcome measure is intended to target those anxiety symptoms that are chronic and pervasive.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  2. Change in Beck Depression Inventory-II (BDI-II) Score From Baseline to Primary Endpoint

    The Beck Depression Inventory-II (BDI-II) is a a 21-item self-reported measure of depression according to Diagnostic and Statistical Manual IV (DSM-IV) criteria. Each item is rated on a 4-point Likert scale ranging from 0 to 3. The total score is the sum of 21 items and range from 0 to 63. Score cutoffs indicate: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, and 29-63 severe depression. Higher scores indicate more severe depressive symptoms.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  3. Change in Global Assessment of Functioning (GAF) Score From Baseline to Primary Endpoint

    The Global Assessment of Function (GAF) is a measure of a person's global social functioning made through clinical observation. The GAF consists of a single score, with scores ranging from 0 to 100, with 100 reflecting superior function and zero reflecting serious risk of causing harm to the self or others.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post 2nd experimental session)

  4. Change in MADRS Score From Baseline to Primary Endpoint

    The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item, clinician administered questionnaire used to diagnose the severity of depressive episodes. Each item has a score of 0 to 6. Overall scores are summed and range from 0 to 60. Score cutoffs indicate: 0-6 normal/symptom absent, 7-19 mild depression, 20-34 moderate depression, > 34 severe depression. Higher scores indicate greater severe depression.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  5. Change in Pittsburgh Sleep Quality Inventory (PSQI) From Baseline to Primary Endpoint

    The Pittsburgh Sleep Quality Index (PSQI) is a measure of self-reported sleep quality over a one month period. It consists of 19 items with possible responses ranging from zero to four on a five-point scale. The PSQI consists of seven sub-scales: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping medications, and daytime dysfunction. These are all summed to produce a single global scale. Global scores can range from 0 to 21, with higher scores reflecting poorer sleep quality, and a score below 5 indicating good sleep quality.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  6. Change in Posttraumatic Growth Inventory (PTGI) From Baseline to Primary Endpoint

    The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  7. Change in Functional Assessment of Chronic Illness Therapy Scale (FACIT) From Baseline to Primary Endpoint

    The Functional Assessment of Chronic Illness Therapy Scale (FACIT-Sp) is a 27-item self-report measure of quality of life issues specifically relevant to individuals with a chronic or life-threatening illness or condition. The core questionnaire consists of four subscales: Physical Well-being, Social/Family Well-being, Emotional Well-being, and Functional Well-being. Responses range from 0 (not at all) to 4 (very much), with higher scores indicating greater well-being. For each subscale, total scores were summed and range from 0 to 16.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  8. Change in Death Attitudes Profile (DAP) From Baseline to Primary Endpoint

    The Death Attitudes Profile (DAP) is a 32-item self-reported questionnaire that assesses individual attitudes and beliefs about death and dying. Each item on the scale is rated along a 7-point Likert scale ranging from "strongly disagree" (score of 1) to "strongly agree" (score of 7), with higher scores indicating more positive attitudes toward death.

    The DAP consists of 5 dimensions: fear of death (7 items summed with total scores ranging from 7 to 49), death avoidance (5 items summed with total scores ranging from 5 to 35), neutral acceptance (5 items summed with total scores ranging from 5 to 35), approach acceptance (10 items summed with total scores ranging from 10 to 70), and escape acceptance (5 items summed with total scores ranging from 5 to 35). For each dimension, a mean scale score can be computed by dividing the total scale score by the number of items forming each scale.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

  9. Change in Self-Compassion Scale (SCS) From Baseline to Primary Endpoint

    The Self-Compassion Scale (SCS) is a 26-item self-reported questionnaire that assesses how respondents relate to themselves and treat themselves during difficult or painful experiences. Items are scored along a 5-point Likert-type scale ranging from 1 "almost never" to 5 "almost always." The SCS has six component (subscale) scores: self-kindness, self-judgment, common humanity, isolation, mindfulness, and over-identification. Subscale scores are calculated by computing the mean of subscale item responses.

    A total self-compassion score is calculated by the sum of the subscale scores and range from 24 to 120 with higher scores indicating greater self compassion. Higher scores have been found to correlate with positive mental health outcomes, as well as decreased depression and anxiety.

    Measured: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2015 (estimated)
  2. Study start14 May 2015
  3. Primary completion25 Apr 2017
  4. Study completion17 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
18 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02427568
Sponsor's protocol ID
MDA-1
Status last verified
May 2025
First submitted
13 Apr 2015
Last updated
5 Jun 2025
Data monitoring committee
No
FDA-regulated device
No
Individual data sharing
Yes: We will share outcome data appearing in any published reports upon request.

Publications

  • Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E, Carlin SC, Sola E, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020 Nov 24;10(1):20442. doi: 10.1038/s41598-020-75706-1.

    PubMed 33235285

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Midomafetamine HCl and Therapy in people with Anxiety, run by Resilient Pharmaceuticals at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Aug 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in State Trait Anxiety Inventory (STAI) Trait Score From Baseline to Primary Endpoint (time frame: Baseline (3 months from enrollment) to Primary Endpoint (one month post-2nd experimental session)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02427568, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in